StackTerminal.Health

Retatrutide (LY-343794)

Investigational triple agonist (GIP/GLP-1/glucagon receptors) studied for obesity; not a dietary supplement. Phase 2 data are robust; phase 3 TRIUMPH program is ongoing.

goal:longevity-metabolic-cardiovasculargoal:metabolicgoal:glucosegoal:lipidsconstraint:not-drug-test-safeevidence:highstudy:rctpop:clinical-populationsform:other
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
—
Max dose
—
Rounding
—
Buy this ingredient← Back

Stacks containing Retatrutide (LY-343794)

Public community stacks that include this ingredient.

Explore all stacks →
metabolicweight-lossclinical-only

Peptides 💀💀💀

by@athlete

Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).

Retatrutide (LY-343794)
1mg
Cagrilintide
1mg
Magnesium (Glycinate)
400mg
New
View
metabolicweight-lossclinical-only

Clinical-only: Metabolic / Weight Loss (Retatrutide + Cagrilintide)

by@athlete

Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).

Retatrutide (LY-343794)
1mg
Cagrilintide
1mg
New
View
recoverysleep

Your personalized stack

by@calm_otter

Built from your goals and the supplement evidence library. You can edit doses and timing.

Caffeine
200mg
Beta-Alanine
3200mg
Vitamin D3
50mg
+ 3 more supplements
New
View
Evidence
2 records
Body weight reduction
Adults with obesity (without diabetes) in a randomized controlled phase 2 trial • Randomized, double-blind, placebo-controlled phase 2 trial
High

Retatrutide produced substantial mean body-weight reductions over 48 weeks (up to ~24% at highest dose), with larger losses at higher doses; GI adverse effects were common and dose-related.

Dose: 12 mg • Duration: 48 weeks
Citation: Jastreboff et al., N Engl J Med (2023) — Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Phase 3 registrational program design (TRIUMPH)
Adults with obesity ± OSA, knee osteoarthritis, or cardiovascular disease (>5800 participants across 4 trials) • Phase 3 registrational program design/rationale publication
Low

The TRIUMPH phase 3 program (4 trials, >5800 participants) evaluates once-weekly subcutaneous retatrutide vs. placebo for weight management and obesity-related complications (OSA, OA, CVD). No primary efficacy results published as of early 2026; design and rationale published in 2025.

Dose: — • Duration: Ongoing (trials projected through 2025–2026)
Citation: Wadden et al., Diabetes Obes Metab (2025) — Retatrutide for obesity, OSA and knee OA: Rationale and design of TRIUMPH
Forms
Lyophilized powder
Research material (vendor listing)